Stay updated on Radical-Dose IGRT in Metastatic NSCLC Clinical Trial
Sign up to get notified when there's something new on the Radical-Dose IGRT in Metastatic NSCLC Clinical Trial page.

Latest updates to the Radical-Dose IGRT in Metastatic NSCLC Clinical Trial page
- Check5 days agoNo Change Detected
- Check19 days agoChange DetectedThe page shows Revision: v3.3.2 replacing v3.2.0, indicating a minor maintenance/version update. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check26 days agoChange DetectedRemoved the notice about lapse in government funding and potential updates to operating status. This does not affect the study details, eligibility criteria, or outcomes listed on the page.SummaryDifference0.4%

- Check34 days agoChange DetectedResults have been posted with estimated results dates (Results First Posted 2025-11-05) and related submission updates (Results First Submitted 2025-06-20), and includes enrollment (45) and study completion dates. Primary and secondary outcomes have been detailed further, including progression-free survival at 24 weeks (RECIST 1.1), overall response, overall survival, and biomarker analyses (circulating tumor DNA and immune markers) along with toxicity data.SummaryDifference3%

- Check49 days agoChange DetectedThe Study Details page for NCT03176173 appears unchanged between the screenshots, including the eligibility criteria, study design, and locations. No new content or deletions affecting user understanding are observed.SummaryDifference0.4%

- Check70 days agoChange DetectedUpgrade to v3.2.0 with a government funding notice and NIH Clinical Center operating details; removes v3.1.0 reference.SummaryDifference4%

- Check77 days agoChange DetectedVersion update: from v3.0.2 to v3.1.0. The change is limited to the revision label; no core content or critical data appears to be altered.SummaryDifference0.1%

Stay in the know with updates to Radical-Dose IGRT in Metastatic NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Radical-Dose IGRT in Metastatic NSCLC Clinical Trial page.